AnaPath
AnaPath Services GmbH is a Swiss-based GLP-certified contract research organization specializing in histopathology, toxicologic pathology, and molecular pathology services for pharmaceutical, biotechnology, chemical, and agrochemical clients across five sites in Switzerland, Spain, and Korea.
- Company typePrivate
- Founded2013
- HeadquartersLiestal, Switzerland
- Headcount101–250
- GTM typeB2B
- OfferingServices
What AnaPath does
AnaPath Services GmbH is a Swiss-based contract research organization (CRO) specializing in histopathology and toxicologic pathology services for the pharmaceutical, biotechnology, chemical, and agrochemical industries. Founded in 2013 in Liestal, Switzerland, the group operates approximately five sites across Switzerland, Spain (AnaPath Research S.A.U., Barcelona), and Korea (AnaPath Korea, established November 2020), employing nearly 200 staff under a founder-led, privately-held ownership structure. Both AnaPath (Oberbuchsiten) and AnaPath Services (Liestal) are GLP-certified by Swiss Medic, with demonstrated experience executing studies to OECD, FDA, and EMA regulatory standards.
The company's core offering spans routine histotechnology (tissue trimming, processing, embedding, H&E staining at a stated capacity of approximately 30,000 tissues per month), diagnostic histopathology and toxicologic pathology by board-certified specialists, necropsy, molecular pathology (immunohistochemistry via Leica BOND-III, tissue cross-reactivity, ISH/FISH, laser capture microdissection, immunofluorescence), developmental and reproductive toxicology (DART) studies, and a suite of special technologies including TEM, SEM with EDX, micro-CT with proprietary MicroAngiofil contrast agent, 3D confocal laser scanning microscopy, and hyperspectral microscopy. Specialized diagnostic services include an extended NASH/NAFLD scoring system, fibrosis characterization, ecotoxicology/endocrine disruptor testing, and plant pollen identification. AnaPath differentiates through deep pathologist expertise (up to 35 years of experience), rare sub-specialty capabilities, and proprietary imaging applications.
Revenue is generated through project-based, quote-based professional services contracts with enterprise clients in pharma, biotech, chemicals, and agrochemicals. Distribution is direct enterprise sales, supplemented by the Safety Alliance network partnership for full Safety Assessment Package delivery and a scientific collaboration with Experimental Pathology Laboratories, Inc (EPL) USA. The firm markets primarily through scientific publications, conference presentations (STP, ECVP, EUROTOX), its website, and a LinkedIn presence. No external funding, M&A activity, or public listing is disclosed, and ownership remains concentrated among founding and senior management stakeholders.
AnaPath firmographics
Firmographics- Name
- AnaPath
- Legal name
- AnaPath Services GmbH
- Website
- https://anapath.ch
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- AnaPath Services GmbH is a Swiss-based GLP-certified contract research organization specializing in histopathology, toxicologic pathology, and molecular pathology services for pharmaceutical, biotechnology, chemical, and agrochemical clients across five sites in Switzerland, Spain, and Korea.
- Ownership category
- akta.pro rank
AnaPath industry classification
Industry- Product category
- Preclinical Contract Research / Histopathology Services
- NAICS
- Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)
- akta.pro secondary industry
- Anatomic Pathology & Histopathology (Trial Support) (HLAGAEAC)
Keywords
Where AnaPath is headquartered
LocationHeadquarters
- HQ city
- Liestal
- HQ country
- Switzerland
- HQ region
- Europe
Offices5 records
Markets served
AnaPath business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: AnaPath operates as a GLP-certified contract research organization (CRO) providing histopathology services to pharmaceutical, biotech, chemical, and agrochemical industries. Revenue is generated through project-based contracts for toxicology and pathology studies, including necropsy, histotechnology, histopathology, molecular pathology, and special technology services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
AnaPath product offering
Product offeringCore offering
AnaPath Services GmbH is a Swiss-based contract research organization (CRO) specializing in histopathology and toxicologic pathology services for pharmaceutical, biotech, chemical, and agrochemical industries. The company delivers GLP-certified laboratory services including histotechnology, histopathology evaluation, necropsy, molecular pathology, developmental and reproductive toxicology (DART) studies, ecotoxicology testing, and advanced imaging technologies such as electron microscopy, micro-CT, confocal and hyperspectral microscopy.
Product overview
AnaPath Services is a contract research organization (CRO) specializing in histopathology and toxicologic pathology services. The company operates as a service-based laboratory rather than a software product company, offering a comprehensive portfolio of diagnostic and analytical services organized into core histopathology services (histotechnology, histopathology, necropsy, molecular pathology, DART studies), special technologies (electron microscopy, micro-CT, confocal/hyperspectral microscopy, laser microdissection), and specialized diagnostic services (NASH/NAFLD scoring, fibrosis assessment, ecotoxicology testing). Services are delivered through GLP-certified facilities in Switzerland, Spain, and Korea with approximately 200 employees across five sites.
Differentiator
Problem solved
Functional benefit
Products and services
- Histotechnology Services
- Histopathology & Toxicologic Pathology
- Necropsy Services
- Molecular Pathology Services
- Developmental and Reproductive Toxicology (DART) Studies
- Electron Microscopy Services
- Micro-CT Imaging
- Confocal and Digital Microscopy
- Hyperspectral Microscopy
- NASH/NAFLD Scoring
- Fibrosis Service
- Ecotoxicology Services
- Plant Pollen Identification and Characterization
- Plasma Ashing Service
- Molecular Biology Services
- Professional Training Services
Quantifiable outcome
- 30,000 tissues processed per month
- +1 more outcomes
Companies that use AnaPath
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
AnaPath technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
AnaPath partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and major.
- AnaPath Research, S.A.U. (Spain)coreAnaPath Research, S.A.U. is the company's research organization in Spain, specifically in Barcelona. This entity conducts complete in vivo safety assessment packages within budget and deadline, extending AnaPath's comprehensive CRO capabilities.
- Safety AlliancecoreSafety Alliance is a network built to support Pharma-, Biotech-, Chemical- and Agrochemical Industries. The partnership allows AnaPath to plan, manage and conduct entire Safety Assessment Packages through this collaborative network.
- Experimental Pathology Laboratories, Inc (EPL) USAmajorActive scientific collaboration with EPL USA for peer reviews mainly in oncogenicity studies, organization of pathology working groups (PWG), education and consulting services.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
AnaPath competitors and assessment
Company assessmentDirect peers
- Histion (now part of Labor LS): Histion was a Denmark-based GLP-certified histopathology CRO serving pharmaceutical, biotech, and medical-device clients with necropsy, histology, and toxicologic pathology services - directly comparable to AnaPath in service mix and customer base. Now operating under Labor LS.
- Experimental Pathology Laboratories (EPL): U.S.-based peer-review pathology and consulting firm specializing in toxicologic pathology, oncogenicity study peer review, and pathology working groups - an existing scientific collaborator of AnaPath with materially overlapping capabilities on the toxicologic pathology review side.
- Sequani: UK-based preclinical CRO offering general toxicology, safety pharmacology, and histopathology services to pharma and biotech clients under GLP. Same customer verticals (pharma/biotech), similar service scope on the pathology and toxicology side, comparable scale.
- Tox Path Sciences (TPS): U.S.-based contract toxicologic pathology firm providing GLP-compliant necropsy, histology, and pathology peer-review services. Overlaps with AnaPath on toxicity pathology, peer-review, and regulatory support for regulated industries.
Broad incumbents
- Citoxlab (now part of Charles River): French-founded preclinical CRO acquired by Charles River offering general toxicology, safety pharmacology, and histopathology across multiple European sites. Comparable GLP histology/toxicology service scope but operates at much greater scale through Charles River.
- Charles River Laboratories: Global preclinical CRO providing Safety Assessment services including toxicology, pathology, and specialty histology. Competes with AnaPath on toxicologic pathology for pharma/biotech clients but at much larger scale and broader service portfolio.
- IDEXX BioResearch: Division of IDEXX providing preclinical and toxicologic pathology, histology, and laboratory services to pharma/biotech. Overlaps with AnaPath on rodent and non-rodent toxicology histopathology with broader test menu.
- WuXi AppTec: Chinese-headquartered global CRO/CDMO with preclinical safety assessment and toxicologic pathology offerings across Asia, North America, and Europe. Competes for multinational toxicology and pathology contracts but at vastly larger scale.
- LabCorp Drug Development / Fortrea: Spin-out of LabCorp's clinical/CRO business (Fortrea) offering preclinical safety assessment, toxicology, and central lab services including histopathology. Larger, full-service alternative for the same pharma/biotech customer base.
Emerging players
- Pharmavize: Belgium-based niche preclinical CRO offering toxicology, pharmacokinetics, and histopathology services to smaller biotech and specialty pharma clients. Smaller scale than AnaPath but overlapping geographic focus on the European preclinical market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
AnaPath social profiles
Digital presenceAnaPath compliance and trust
Trust signalCompliance1 record
AnaPath financial estimates
Financial estimateRevenue estimate
Valuation estimate
AnaPath leadership team
Management profileNumber of profiles
Profiles9 records
AnaPath subsidiaries and ownership
Company hierarchySubsidiaries4 records
AnaPath funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AnaPath M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AnaPath
What does AnaPath do?
AnaPath Services GmbH is a Swiss-based contract research organization (CRO) specializing in histopathology and toxicologic pathology services for pharmaceutical, biotech, chemical, and agrochemical industries. The company delivers GLP-certified laboratory services including histotechnology, histopathology evaluation, necropsy, molecular pathology, developmental and reproductive toxicology (DART) studies, ecotoxicology testing, and advanced imaging technologies such as electron microscopy, micro-CT, confocal and hyperspectral microscopy.
Is AnaPath a public or private company?
AnaPath is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AnaPath founded?
AnaPath was founded in 2013. It employs 101 to 250 people.
Where is AnaPath based?
AnaPath is headquartered in Liestal, Switzerland, in the Europe region.
How does AnaPath make money?
One revenue line is on record: contract Research Services.
Who are AnaPath's main competitors?
Direct peers on record are Histion (now part of Labor LS), Experimental Pathology Laboratories (EPL), Sequani and Tox Path Sciences (TPS). Broad incumbents are Citoxlab (now part of Charles River), Charles River Laboratories, IDEXX BioResearch, WuXi AppTec and LabCorp Drug Development / Fortrea. Pharmavize is listed as an emerging player.
Does AnaPath have an API?
No public API is recorded for AnaPath.
What industry is AnaPath in?
AnaPath's product category is Preclinical Contract Research / Histopathology Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAEAC, Anatomic Pathology & Histopathology (Trial Support). Its NAICS code is 5417 and its SIC code is 8071.